A relative methylation ordering biomarker of lactylation-related genes predicts prognosis and therapeutic response in cutaneous melanoma
An epigenetic fingerprint stratifies melanoma patients into distinct risk groups and predicts immunotherapy versus chemotherapy sensitivity.
CM-LP11, a novel 11-methylation-pair prognostic model derived from lactylation-related gene loci, robustly stratified cutaneous melanoma patients into risk groups across three independent cohorts and identified differential immunotherapy vs chemotherapy sensitivity. This epigenetic approach using relative methylation ordering provides a potentially non-invasive prognostic tool for melanoma management, though prospective validation is needed.
What the study was
- Study design
- Retrospective bioinformatics study with multi-cohort validation
- Population
- Cutaneous melanoma patients (TCGA n=458 training; two validation cohorts n=241)
- Sample size
- 699
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Epigenetics
Why it surfaced
Multi-cohort validated methylation prognostic model for melanoma with novel lactylation biology angle. Bioinformatics study; prospective clinical utility unproven.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.